Skip to main content
Premium Trial:

Request an Annual Quote

EPO Upholds Claims in Silence Cancer Drug Patent

Premium

Silence Therapeutics said this week that the European Patent Office has upheld an amended form of a patent covering protein kinase N beta, which is silenced with the company's phase I cancer drug Atu027.

Silence said the patent covers the use of PKN3 as a downstream target of the PI3 kinase pathway; the use of PKN3 as a downstream drug target of the PI3 kinase pathway in a screening process; the manufacture of a diagnostic agent based on use of PKN3; and the use of molecules such as siRNAs against PKN3 as a therapeutic.

In its amended form, the patent limits to metastatic cancers the diseases for which PKN3 inhibition can be used as a treatment.

"We are very pleased with the outcome of this oral opposition hearing, which has upheld the key part of our claims in this granted patent,” Silence CEO Thomas Christely said in a statement.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.